Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC

Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond to first generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFR T790M mutation....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Walter, Annette O., Sjin, Robert Tjin Tham, Haringsma, Henry J., Ohashi, Kadoaki, Sun, Jing, Lee, Kwangho, Dubrovskiy, Aleksander, Labenski, Matthew, Zhu, Zhendong, Wang, Zhigang, Sheets, Michael, Martin, Thia St, Karp, Russell, van Kalken, Dan, Chaturvedi, Prasoon, Niu, Deqiang, Nacht, Mariana, Petter, Russell C., Westlin, William, Lin, Kevin, Jaw-Tsai, Sarah, Raponi, Mitch, Dyke, Terry Van, Etter, Jeff, Weaver, Zoe, Pao, William, Singh, Juswinder, Simmons, Andrew D., Harding, Thomas C., Allen, Andrew
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4048995/
https://ncbi.nlm.nih.gov/pubmed/24065731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0314
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars